Distinctive ReJI foundations
The investment case combines a differentiated printing process, platform development and an IP position available through controlled diligence.
For investors
Fund commercial proof, not just technical promise.
JetBio is building a capital-efficient route from university research and research deployments to a focused, applications-led commercial platform.
The proposition
A focused route to commercial traction.
The near-term strategy runs funding and customer validation together. Capital supports the product, evidence and commercial system needed to convert credible research interest into paid feasibility work and, subject to validation, repeatable system sales.
Research deployment learning
University settings provide application feedback and help define the commercial specification.
Application-led entry
Initial effort centres on well-defined in vitro model use cases, not the whole bioprinting market.
Investment priorities
What the next capital unlocks.
- 01
Product definition
Freeze commercial configurations, specifications, quality requirements, service boundaries and regulatory position.
- 02
Application evidence
Generate repeatable datasets and buyer-facing proof for the first commercial wedges.
- 03
Commercial conversion
Build the feasibility offer, pipeline discipline, sales materials, qualification process and customer support route.
- 04
Manufacturing readiness
Prepare supply chain, build documentation, quality controls and delivery capacity for repeatable systems.
Public materials do not present letters of interest, grant-funded placements or research collaborations as revenue, orders or completed commercial sales. Forecasts, valuation, use of funds and diligence materials are available through the controlled investor process.
Start a useful conversation
Request the investment case and diligence pathway.
We will share the current deck, milestone plan and controlled supporting evidence with suitable investors.